RhumbLine Advisers’s Alpine Immune Sciences Inc ALPN Stock Holding History

RhumbLine Advisers’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-54,543	Closed	-$2.16M	–	4395
2024 Q1	$2.16M	Buy	54,543 +10,822	+25%	+$319K	﹤0.01%	1871
2023 Q4	$833K	Buy	43,721 +2,318	+6%	+$32.2K	﹤0.01%	2363
2023 Q3	$474K	Buy	41,403 +1,977	+5%	+$24.3K	﹤0.01%	2639
2023 Q2	$405K	Buy	39,426 +6,578	+20%	+$59.3K	﹤0.01%	2823
2023 Q1	$254K	Buy	32,848 +6,615	+25%	+$52.7K	﹤0.01%	2668
2022 Q4	$193K	Buy	26,233 +4,496	+21%	+$28.7K	﹤0.01%	2799
2022 Q3	$157K	Buy	21,737 +1,333	+7%	+$11K	﹤0.01%	2940
2022 Q2	$174K	Buy	+20,404	New	+$176K	﹤0.01%	2967

RhumbLine Advisers's ALPN Position: Q2 2024 in Review

RhumbLine Advisers sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 54,543 shares — an estimated $2.16M sold.

RhumbLine Advisers first reported a position in ALPN in Q2 2022 and held it in 8 quarters. The position peaked at $2.16M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

RhumbLine Advisers reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
RhumbLine Advisers sold 54,543 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $2.16M.
RhumbLine Advisers first reported a position in Alpine Immune Sciences Inc in Q2 2022 and held it in 8 quarters.
RhumbLine Advisers's Alpine Immune Sciences Inc position peaked at $2.16M in Q1 2024.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on RhumbLine Advisers's 13F filing for Q2 2024, filed 1 Aug 2024.